| HOME >> MEDICINE >> TECHNOLOGY |
1,9811,645Commitments and contingenciesStockholders' equityPreferred stock, $.01 par value - authorized 50,000,000shares, none issued and outstandingCommon stock, $.01 par value - authorized 2,000,000,000shares and issued 1,531,013,482 shares as of September 30, 2011
1515and 1,520,780,112 shares as of December 31, 2010Treasury stock, at cost - 30,000,000 shares as of September 30, 2011
(192)Additional paid-in capital
16,31816,232Accumulated deficit
(4,488)(4,822)Accumulated other comprehensive loss, net of tax
(132)(129)Total stockholders' equity
11,52111,296$
21,502$
22,128BOSTON SCIENTIFIC CORPORATIONNON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)Three Months Ended September 30,20112010ImpactImpactNetper dilutedNetper dilutedin millions, except per share data
incomeshareincomeshareGAAP net income$ 142$
.09$
90$
.12Non-GAAP adjustments:Intangible asset impairment charges
7
0.014
0.00Acquisition-related charges
7
0.01Divestiture-related net credits
(5)
0.00Restructuring-related charges
19
0.0114
0.01Discrete tax items
(25)
(0.02)(21)
(0.01)Amortization expense
78
0.05109
0.07Adjusted net income$ 223$
.15$
296$
.19Nine Months Ended September 30,20112010ImpactNetImpactNetper diluted(loss)per dilutedin millions, except per share data
incomeshareincomeshareGAAP net income (loss)$ 334$
.22$ (1,301)$
(0.86)Non-GAAP adjustments:Goodwill impairment net charges
697
0.451,817
1.20 *Intangible asset impairment charges
16
0.0155
0.03 *Acquisition-related net credits
(17)
(0.01)(216)
(0.14) *Divestiture-related net credits
(533)
(0.35)Restructuring-related charges
75
0.0599
0.06 *D
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved |